ĭetermining when a patient with asthma or chronic obstructive pulmonary disease becomes prone to exacerbation. Even a brief use of systemic corticosteroids to treat exacerbations can greatly increase the risk of venous thromboembolism, sepsis, and fracture. These patients incur approximately two-thirds of all exacerbations and experience a low quality of life sleep disturbance limitations of daily activities impacting independence, relationships, family life, socialization, and career anxiety distress missed work with lost earnings missed school high care costs high hospital use intubation and death. Approximately one-fourth of patients with asthma and patients with COPD are prone to exacerbation, meaning that a patient has (1) ≥2 systemic corticosteroid orders in a year or (2) ≥1 emergency department visit or inpatient stay for asthma or COPD with systemic corticosteroid treatment in a year ( Figure 1). One main goal in managing patients with asthma and patients with COPD is to reduce exacerbations, which expend approximately 40% to 75% of their total care cost and accelerate their lung function decline. Approximately 6.5% of adults have chronic obstructive pulmonary disease (COPD), the third leading cause of death, leading to 1.5 million emergency department visits, 0.7 million inpatient stays, and US $32 billion in cost every year. In the United States, 9.6% of children and 8% of adults have asthma, leading to 1.8 million emergency department visits, 493,000 inpatient stays, US $56 billion in cost, and 3630 deaths every year. Management of Asthma and Chronic Obstructive Pulmonary Disease Regular automatic explanation methods cannot deal with temporal data and address this issue well. Second, existing models seldom show the reason a patient is deemed high risk and the potential interventions to reduce the risk, making already occupied clinicians expend more time on chart review and overlook suitable interventions. First, existing models for other asthma and COPD outcomes rarely use more advanced temporal features, such as the slope of the number of days to albuterol refill, and are inaccurate. It would be suboptimal to build such models using the current model building approach for asthma and COPD, which has 2 gaps due to rarely factoring in temporal features showing early health changes and general directions. To do this well, a predictive model for proneness to exacerbation is required, but no such model exists. Approximately one-fourth of patients with asthma and patients with COPD are prone to exacerbations, which can be greatly reduced by preventive care via integrated disease management that has a limited service capacity. Asthma and chronic obstructive pulmonary disease (COPD) impose a heavy burden on health care.

Provantage nitro pdf software